MedTrace Logo

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

NCT05297578 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2024-10-09

Study results available
· View outcomes & findings →

Summary

The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.

Conditions

  • Pneumococcal Vaccines

Interventions

BIOLOGICAL

24-Valent Pneumococcal Conjugate Vaccine

0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1

BIOLOGICAL

Pneumococcal 20-valent Conjugate Vaccine

0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1

Sponsors & Collaborators

  • Vaxcyte, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Development · Vaxcyte, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2023-02-15
Completion
2023-02-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05297578 on ClinicalTrials.gov